EUCTR2020-004534-38-FR进行中（未招募）1 期
A Randomized, Double-blind, Placebo-controlled, Phase 2b Study to Evaluate Safety and Efficacy of DUR-928 in subjects with Alcoholic Hepatitis
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Able to provide written informed consent (either from subject or subject’s legally acceptable representative)
- •2. Onset of jaundice within prior 8 weeks
- •3. Average daily consumption of > 40 (females) or > 60 (males) grams alcohol for 6 months or longer, with < 8 weeks of abstinence before the onset of jaundice. Judgment regarding daily and long-term alcohol use and onset of jaundice will be made by the site investigator.
- •4. The determination of AH may be based on typical serum chemistry (as determined by local laboratory) or liver biopsy at any time during the current episode of AH:
- •Serum total bilirubin > 3.0 mg/dL
- •50 < AST < 400 IU/L
- •ALT < 400 IU/L
- •AST/ALT > 1.5
- •NOTE: Labs values on the day of randomization must include serum total bilirubin > 3.0 mg/dL and AST and ALT < 400 IU/L in addition to the MDF and MELD values in inclusion 5 and 6 below.
- •5. Maddrey discriminant function (MDF) = 32 assuming a control prothrombin time of 12 seconds NOTE: If a local laboratory’s control time differs from 12 seconds then the local laboratory’s control time should be used.
- •6. Model for End-stage Liver Disease (MELD) score: 21-30
- •7. Liver biopsy is not required, but may be used to confirm the diagnosis of AH at the Investigator’s discretion. Biopsy, if used as a diagnostic criterion, must have occurred during the current episode. NOTE: Liver biopsy is not a study procedure and will not be reimbursed.
- •8. Male or female subjects 18 years of age or older
- •9. Women of child-bearing potential (defined as females who are not surgically sterile or who are not over the age of 52 and amenorrheic for at least 12 months) must utilize appropriate birth control throughout the study duration. Acceptable methods that may be used are abstinence, birth control pills (The Pill”) or patch, diaphragm, IUD (coil), vaginal ring, condom, surgical sterilization or progestin implant or injection, or sexual activity limited to a sterile (e.g., vasectomized) male partner.
- •10. Male subjects must agree to use a medically acceptable method of contraception/birth control and refrain from sperm donation throughout the study duration
- •11. Subjects must agree to participate in an alcohol abstinence support program recommended by the local institution’s addiction specialists
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 200
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •1. Subjects taking systemic corticosteroids for a duration exceeding 8 days in the 30 days prior to screening. NOTE: Inhaled, topical, or local corticosteroid injections are permitted
- •2. Subjects experiencing or considered at high risk for alcohol withdrawal seizures or delirium tremens
- •3. Active infection (such as spontaneous bacterial peritonitis [SBP], urinary tract infection [UTI], bacteremia, acute viral hepatitis, uncontrolled HIV, and active SARS CoV2 infection).
- •a. Subjects who are febrile with leukocytosis are also excluded until active infection has been excluded to the satisfaction of the PI in consultation with the medical monitor.
- •b. Patients with bacterial peritonitis may be considered for enrollment once the infection has been treated and follow up paracentesis confirms the absence of SBP.
- •c. Patients with fungal infection of any kind cannot be considered for this trial.
- •4. Serum creatinine >2.5 mg/dL
- •5. Criterion removed as part of Protocol Amendment 2, but placeholder kept to maintain consistency in subsequent criteria numbering
- •6. Subjects undergoing continuous veno-venous hemodialysis (CVVH)
- •7. Uncontrolled gastrointestinal bleeding
- •8. A history of pre-admission refractory ascites defined as more than 4 paracenteses in the previous 8 weeks despite diuretic therapy.
- •9. Liver biopsy (if carried out) with findings not compatible with AH
- •10. Stage = 3 hepatic encephalopathy by West Haven criteria
- •11. Any severe concomitant cardiovascular, renal, endocrine, pulmonary (including ventilator dependent or COPD Global Obstructive Lung Disease [GOLD] stage III or IV), psychiatric disorder, or multi-organ failure
- •12. Other concomitant cause(s) of liver disease as a result of:
- •a. Autoimmune liver disease
- •b. Ischemic hepatitis
- •c. Wilson disease or alpha 1 antitrypsin deficiency
- •d. Vascular liver disease (e.g., Budd-Chiari)
- •e. Drug induced liver disease
- •f. Surface antigen positive hepatitis B (HBsAg+). NOTE: subjects with isolated core antibody (anti-HBc) or who are on stable antiviral medication with known viral suppression are not excluded
- •g. Acute hepatitis A (if test performed per SOC)
- •h. Acute HCV or chronic hepatitis C with a history of decompensated cirrhosis. NOTE: subjects with stable chronic HCV or successfully treated HCV are not excluded
- •i. Acute hepatitis E (if test performed per SOC)
- •j. Acute cytomegalovirus (CMV) viral hepatitis (if test performed per SOC)
- •k. Acute Epstein-Barr virus (EBV) viral hepatitis (if test performed per SOC)
- •NOTE: A spurious finding, such as the incidental finding of moderately elevated antinuclear antibody (ANA) or anti-smooth muscle antibody (ASMA) titer is not, by itself, a mandatory exclusion criterion unless accompanied by other evidence suggestive of a probable disease other than AH.
- •13. Any active malignancy or any malignancy diagnosed within the last five years other than curable skin cancer (basal cell or squamous cell carcinomas)
- •14. Positive Urine Drug Screen (amphetamines, barbiturates, benzodiazepines, cocaine and opiates) except THC and prescription medications
- •15. Existing or intended pregnancy or breast feeding
- •16. Participation in another interventional clinical trial within 30 days of Screening
- •17. History of organ transplantation, other than a corneal transplant
- •18. Underlying diseases that, in the opinion of the site investigator, might be complicated or exacerbated by proposed treatments or might confound assessment of study drug
研究者
相似试验
进行中（未招募）
1 期
A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 TreatmentMedDRA version: 20.0Level: LLTClassification code 10001624Term: Alcoholic hepatitisSystem Organ Class: 100000004871Alcoholic hepatitisEUCTR2020-004534-38-DEDURECT Corporation300
进行中（未招募）
不适用
A Clinical Trial Investigating OSI-906 in Patients with Adrenocortical CarcinomaAdrenocortical CarcinomaMedDRA version: 14.1Level: PTClassification code 10001388Term: Adrenocortical carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-012820-97-DEAstellas Pharma Global Development, Inc.135
招募中
3 期
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Metastatic Breast CancerBreast carcinoma10006291Breast cancerNL-OMON51870Merck Sharp & Dohme (MSD)24
进行中（未招募）
不适用
A study of AMG 416 in the treatment of secondary hyperparathyroidism in chronic kidney diseaseSecondary hyperparathyroidism in subjects with chronic kidney diseaseMedDRA version: 17.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersMedDRA version: 17.0Level: LLTClassification code 10020706Term: Hyperparathyroidism NOSSystem Organ Class: 10014698 - Endocrine disordersEUCTR2012-002805-23-ATKAI Pharmaceuticals, Inc (a subsidiary of Amgen, Inc.)500
进行中（未招募）
1 期
A phase 3 randomised, double-blind, placebo-controlled efficacy and safety study funded by Furiex Pharmaceuticals. The purpose of this study is to find out if a new investigational drug called JNJ-27018966 is safe and effective as a treatment for diarrhea-predominant Irritable Bowel Syndrome (IBS-d).Diarrhea-predominant irritable bowel syndromeMedDRA version: 20.1 Level: LLT Classification code 10060845 Term: Diarrhea predominant irritable bowel syndrome System Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 20.1 Level: PT Classification code 10023003 Term: Irritable bowel syndrome System Organ Class: 10017947 - Gastrointestinal disordersEUCTR2012-001600-38-GBFuriex Pharmaceuticals1,282